Eris Lifesciences Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Eris Lifesciences's estimated annual revenue is currently $54.3M per year.
- Eris Lifesciences's estimated revenue per employee is $201,000
- Eris Lifesciences has 270 Employees.
- Eris Lifesciences grew their employee count by 20% last year.
- Eris Lifesciences currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
What Is Eris Lifesciences?
The journey of Eris Lifesciences began in 2007, focusing on the chronic drug segments of cardiology and diabetes. This Ahmedabad based emerging pharmaceutical major now ranks among the top 25 pharmaceutical companies in the Indian Pharmaceutical Market (IPM). In 2017, Eris made a public offer of its shares and is listed on the Bombay Stock Exchange (Code: 540596) and National Stock Exchange (Code: ERIS). Eris derives 66% of its revenues from the chronic segment, where it ranks among the top 20 players in the cardio and anti-diabetes therapeutic groups in the IPM. Recently, Eris forayed into the Central Nervous System (CNS) category, strengthening its presence in the top three chronic segments. The Company also has the biggest market share for the Vitamin D product. The genesis of Eris was rooted in the understanding of healthcare delivery gaps in an emerging country like India. Realizing the challenges of poor diagnosis, poor patient compliance, population-provider burden, etc. and the limitations of a single company to address these challenges, Eris adopted a partnering mindset and approach by aligning with like-minded institutions and adopting innovative programmes for engagement. Eris Lifesciences is a young company which imbibes qualities of youth - imagination, courage and passion.keywords:N/A
Number of Employees
Employee Growth %
Eris Lifesciences News
As with many other companies Eris Lifesciences Limited (NSE:ERIS) makes use of debt. But should shareholders be worried about its use of ...
Unfortunately the Eris Lifesciences Limited (NSE:ERIS) share price slid 40% over twelve months. That contrasts poorly with the market return of ...
This acquisition will help in establishing Eris Lifesciences Limited as one of the top ten companies worldwide for Central Nervous System ...